LY6K and cancer: Furthermore, 5-year survival in esophageal cancer patients treated with a cancer peptide vaccine including URLC10, CDCA1, and KOC1 was significantly higher than in untreated patients (68.0% versus 17.7%; p = 0.010) in the sub-population defined as CD8(–)/PD-L1(–) [35].